Literature DB >> 18541987

Topiramate may modulate alcohol abuse but not other compulsive behaviors in frontotemporal dementia: case report.

Marcelo Cruz1, Valeska Marinho, Leonardo F Fontenelle, Eliasz Engelhardt, Jerson Laks.   

Abstract

Frontotemporal dementia (FTD) is an insidious presenile neurodegenerative disorder presenting with personality changes, compulsive behaviors, psychosis, apathetic, aberrant, and elated mood and behavior. No psychopharmacologic strategy has proven to be efficacious in the treatment of FTD yet. This is a case report of FTD in a 53-year-old male engineer whose alcohol abuse, but not other compulsive behaviors, responded to topiramate. Alcohol exerts reinforcing effects on cortico-mesolimbic dopamine pathways through the disinhibition of the inhibitory effects of gamma-amino-butyric acid-A neurons in the ventral tegmental area. Topiramate is a sulfamate-substituted fructopyranose derivative that may antagonize the reinforcing effects associated with the abuse liability of alcohol by modulation of cortico-mesolimbic dopamine function. On the basis of the mechanism of action of topiramate, we discuss the possible specificity of action of topiramate to control abusive drinking, but not to treat other clinical symptoms of FTD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18541987     DOI: 10.1097/WNN.0b013e31816bdf73

Source DB:  PubMed          Journal:  Cogn Behav Neurol        ISSN: 1543-3633            Impact factor:   1.600


  15 in total

1.  Substance use history in behavioral-variant frontotemporal dementia versus primary progressive aphasia.

Authors:  Raj K Kalapatapu; Kevin L Delucchi; Sophia Wang; John D Harbison; Emily E Nelson; Joel H Kramer
Journal:  J Addict Dis       Date:  2015-10-20

2.  Neuropsychiatric symptoms in primary progressive aphasia: phenomenology, pathophysiology, and approach to assessment and treatment.

Authors:  Mandana Modirrousta; Bruce H Price; Bradford C Dickerson
Journal:  Neurodegener Dis Manag       Date:  2013-04-01

3.  Treatment of frontotemporal dementia.

Authors:  Richard M Tsai; Adam L Boxer
Journal:  Curr Treat Options Neurol       Date:  2014-11       Impact factor: 3.598

Review 4.  Therapy and clinical trials in frontotemporal dementia: past, present, and future.

Authors:  Richard M Tsai; Adam L Boxer
Journal:  J Neurochem       Date:  2016-06-15       Impact factor: 5.372

Review 5.  Medical management of frontotemporal dementias: the importance of the caregiver in symptom assessment and guidance of treatment strategies.

Authors:  Gregory A Jicha
Journal:  J Mol Neurosci       Date:  2011-06-07       Impact factor: 3.444

6.  Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options.

Authors:  Gregory A Jicha; Peter T Nelson
Journal:  Neurodegener Dis Manag       Date:  2011-04

Review 7.  Frontotemporal Dementia.

Authors:  Nicholas T Olney; Salvatore Spina; Bruce L Miller
Journal:  Neurol Clin       Date:  2017-05       Impact factor: 3.806

Review 8.  New approaches to the treatment of frontotemporal lobar degeneration.

Authors:  Keith A Vossel; Bruce L Miller
Journal:  Curr Opin Neurol       Date:  2008-12       Impact factor: 5.710

9.  Anatomical correlates of reward-seeking behaviours in behavioural variant frontotemporal dementia.

Authors:  David C Perry; Virginia E Sturm; William W Seeley; Bruce L Miller; Joel H Kramer; Howard J Rosen
Journal:  Brain       Date:  2014-04-16       Impact factor: 13.501

10.  Repetitive Behaviors in Frontotemporal Dementia: Compulsions or Impulsions?

Authors:  Negar Moheb; Kanida Charuworn; Mark M Ashla; Randy Desarzant; Diana Chavez; Mario F Mendez
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2018-12-12       Impact factor: 2.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.